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ABSTRACT 
PREDICITING SUCCESSFUL CHAPERONING OF FABRY DISEASE MUTANTS VIA 
COMPUTATION 
 
SEPTEMBER 2019 
PRIYANK PATEL, B.S., UNIVERSITY OF MASSACHUSETTS, AMHERST 
M.S., UNIVERSITY OF MASSACHUSETTS, AMHERST 
Directed By: Dr. Scott Garman 
Fabry disease is an inherited X-linked recessive disorder caused by mutations in the 
galactosidase alpha (GLA) gene, leading to deficiencies in α-galactosidase A (α-GAL) enzyme 
production. α-GAL, a lysosomal glycosidase, catalyzes the removal of a terminal α-galactose; 
however, loss of α-GAL activity leads to accumulation of globotriaosylceramide (an endogenous 
substrate) and the eventual onset of the disease. Approved treatments for Fabry disease include 
enzyme replacement therapy and pharmacological chaperone therapy. In the latter treatment, 1-
deoxygalactonojirimycin (DGJ), a pharmacological chaperone, is administered to Fabry disease 
patients, leading to increased enzymatic activity. The DGJ iminosugar acts as a competitive 
inhibitor of α-GAL, and upon addition at sub-inhibitory concentrations, the α-GAL activity in 
the cell increases. At pH 7.5, the DGJ binds and stabilizes both wild type and mutant α-GAL and 
can thus drive the folding of the α-GAL protein (Guce 2011). DGJ has been clinically approved 
to treat a subset of the more than 900 known mutations in the GLA gene. These approvals come 
from the chaperone activity data published by Amicus Therapeutics (Benjamin 2017). However, 
these assays cost money, time, and effort to perform, and novel mutations are discovered 
annually. Using molecular dynamics energy calculations in the Schrödinger software package, 
we developed a model to predict successful chaperoning of the mutants. Overall, the results are
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directly applicable to Fabry disease, but could also be applied to the much larger family of 
protein folding diseases, including Alzheimer's, Parkinson's and Huntington's diseases. 
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CHAPTER 1 
INTRODUCTION 
1.1 Lysosomal Storage Disorders  
The lysosome is a membrane-enclosed organelle responsible for the catabolism of 
macromolecules into smaller metabolites that are either secreted or recycled by the cell. These 
biological polymers are broken down by acid hydrolases that are synthesized in the endoplasmic 
reticulum and trafficked to the lysosome. The organelle maintains a low pH, required for the 
enzymes to be active, via a proton pump that takes protons from the cytosol and is coupled to an 
ATP hydrolysis reaction (Cooper 2000).  
  
Figure 1.1 – The Lysosome acts as the recycling center of the cell. Left – Acid hydrolases are 
active at low pH which is regulated by a proton pump. Right – Lysosomal storage disorders 
manifest when substrate accumulates within the lysosome due to a deficiency of an acid 
hydrolase (The Cell: A Molecular Approach. 2nd Edition – Lysosomes). 
 
In patients who have lysosomal storage disorders, substrates accumulate within the 
lysosome due to a deficiency in the acid hydrolases required to break them down. There are close 
to fifty of these diseases, and the rate of incidence in the human population is approximately 1 in 
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8000 live births. Some reasons that enzyme may be deficient include: the lack of a transporter or 
activator, the presence of a mutation in the gene encoding for the protein, or the inability of a 
misfolded enzyme to traffic properly to the lysosome (Greiner-Tollersrud 2000). 
 
Figure 1.2 – An electron micrograph of a vacuolated lymphocyte in a patient with alpha-
mannosidosis, a lysosomal storage disease. The panel on the left shows enlarged vacuoles (in 
white) due to the accumulation of substrate in the lysosome (Malm and Nilssen 2008).  
 
1.2 Fabry Disease 
Fabry Disease (FD), a lysosomal storage disorder, is an inherited X-linked recessive disease 
that occurs due to a deficiency in the acid hydrolase, alpha-galactosidase (GLA). Mutations in 
the GLA gene encoding for the enzyme result in substrate accumulation of globotriaosylceramide 
(Gb3) due to misfolding or an inability to traffic to the lysosome (Mehta 2006). These deposits 
can lead to severe phenotypes such as angiokeratomas, hypertrophic cardiomyopathy, white 
matter hyperintensity in the brain, and renal failure. Although it is a rare monogenetic disease 
(FD affects 1 in 40,000 – 60,000 males), studies of the disease can be applied to other protein 
folding diseases, such as Alzheimer’s, Parkinson’s and Huntington’s diseases (Germain 2010). 
 
 3 
 
 
Figure 1.3 – The GLA gene is located on the X-chromosome and defective copies are inherited 
in a recessive fashion (NIH – GLA Gene). 
 
 
Figure 1.4: Structures of the enzyme and substrate. Left - Crystal structure of the apo 
homodimer α-galactosidase (PDB ID: 3S5Y). Right – The glycosphingolipid Gb3, the 
endogenous substrate of α-galactosidase. R is a carbon aliphatic chain.  
 
1.3 Reaction Mechanism 
The terminal α-D-galactose is cleaved from Gb3 via a hydrolysis reaction. The reaction is 
classified as a double displacement reaction where Asp170 acts as a nucleophile and Asp231 acts 
as a catalytic acid-base pair. Since its pKa is lower than the pH of the ER or the lysosome, the 
negatively-charged carboxylate oxygen in Asp170 attacks the glycosidic bond and creates a 
covalent bond between Asp170 and α-D-galactose. Lactosylceramide leaves the active site after 
it strips the hydrogen off of Asp231. A water molecule is broken apart as Asp231 takes a 
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hydrogen, and the hydroxyl group attacks the 1-position carbon as Asp170 returns to its native 
state. A cleaved α -galactose is created (Guce 2010). 
 
 
Figure 1.5: Reaction mechanism of alpha-galactosidase cleaving the terminal galactose from a 
glycosphingolipid.  
 
1.4 GLA Mutations 
There is a well-established database of mutations that occur in the GLA gene that result in 
FD. There have been nearly 900 reported mutations and nearly 500 have been tested for activity 
in cell lysates (Benjamin 2017). The work presented in this thesis will focus on missense 
mutations since they make up the majority of mutations in FD patients and are easier to model 
computationally.  
1.5 Pharmacological Chaperone Therapy 
There are many treatment options available for lysosomal storage disorders including: 
hematopoietic stem cell therapy, substrate reduction therapy, enzyme-replacement therapy 
(ERT), and pharmacological chaperone therapy (PCT). For FD patients, ERT and PCT are the 
leading options for treatment; however, ERT is incredibly expensive (around 250,000 USD 
annually) and inconvenient (requires a biweekly intravenous infusion) (Desnick 2001). PCT 
involves the use a small molecule chaperone that binds the enzyme to shift the folding 
equilibrium from unfolded or misfolded to folded. The theory is that the chaperone will bind the 
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mutant enzyme in the endoplasmic reticulum (ER) at neutral pH (~7.2), help the enzyme fold to 
avoid degradation by the proteasome, traffic to the lysosome via the mannose-6-phosphate-
receptor, and dissociate at low pH to restore enzymatic activity.  
 
  
 
Figure 1.6: Pharmacological chaperone therapy is an approved treatment plan for FD patients. 
Left – In FD patients, the protein is unable to fold properly and is therefore degraded by the 
proteasome. Right – The folding equilibrium shifts to the native state, allowing for the detection 
of the receptor to traffic to the lysosome to catabolize its substrates (Parenti 2009). 
 
1.6 1-deoxygalactonojirimycin 
The pharmacological chaperone, 1-deoxygalactonojirimycin (DGJ), was approved for the 
treatment of FD in 2016 by the FDA. It is a competitive iminosugar inhibitor (Ki = 39 nM) that 
binds with higher affinity to GLA than galactose (Ki = 16 mM). They differ by a nitrogen atom 
replacing the oxygen atom in the ring and by the lack of a hydroxyl group on the 1-position 
carbon. These two changes produce an incredible 400,000-fold more potent inhibitor that can 
restore the proper tertiary fold to the enzyme. DGJ also slows the unfolding kinetics of GLA and 
stabilizes the enzyme at neutral and low pH (Guce 2011).  
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Figure 1.7: DGJ binds with higher affinity than its endogenous substrate analog, galactose. Left 
– Structure of DGJ. Right – Structure of galactose.  
 
1.7 Hypothesis 
The biological experimental data from Amicus is useful to determine successful chaperoning 
of the small molecule inhibitor, DGJ. However, these assays take time, money, and effort to 
perform. There are also multiple crystal structures of the enzyme, GLA, in the unbound and 
bound states. The motivation behind creating a computational algorithm exists to decrease the 
aforementioned cons of determining chaperoning ability.  Using the coordinates from the Protein 
Data Bank and the experimental cellular data, we can attempt to predict which mutants will be 
rescuable upon addition of DGJ. The goal is to train the set of mutants that have published 
activity data via computations and to apply this protocol for novel mutations. The idea is that 
there is a correlation between the energetics of the complex to chaperoning success. 
Computations will attempt to predict energies of binding to different mutants and the outputs will 
be compared to the activity data.  
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CHAPTER 2 
ENERGETICS CALCULATIONS OF FABRY DISEASE MUTANTS USING 
DIFFERENT POTENTIAL ENERGY TASKS AND BIOCHEMICAL 
CHARACTERIZATION OF DIFFERENT CLASSES OF MUTANTS 
2.1 Introduction 
 Previous energetics calculations were performed using the Residue Analysis task from 
the Schrödinger Software’s biologics package. The calculations were based on the following 
model (Figure 2.1). WT enzymes begin folding in the ER at neutral pH and eventually traffic to 
the lysosome via the aid of a mannose-6-phosphate receptor to function at acidic pH. In the 
mutant pathway, the folding equilibrium has shifted to the unfolded state and thus becomes 
targeted for proteasomal degradation. However, when the small molecule chaperone is 
introduced, the folding equilibrium shifts towards the native state, thus allowing the mutant to 
refold in the ER. The small molecule eventually dissociates from the enzyme at low pH due to a 
shift in protonation states of the ligand, allowing its endogenous substrates to bind and be 
cleaved.  The three axes to note in this model are shown on the left (Figure 2.1). The Residue 
Analysis task calculates the potential, interaction, and internal energies of the system.  
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Figure 2.1: The old energetics model involves calculating the total energy at different points in 
this box, namely the folded, folded with ligand, and active states. 
 
 
 
Additionally, a biochemical characterization was performed by binning mutations by amino 
acid. Certain mutations may be amenable for rescuing by the chaperone, depending on the 
residue transition. These results are shown in Table 2.3. 
The proposed model involves a thermodynamic cycle that has been proven to work for other 
model systems (Beard 2013, Sarkar 2016). In a thermodynamic cycle, the sum of the energies, in 
this case the state variable Gibbs free energy, will be zero. We know the free energy of binding 
DGJ to the WT GLA. We can calculate energy differences between WT and mutant and bound 
WT and bound mutant using Prime Energy. After measuring these three energies, we can 
calculate the rescue free energy to see if binding DGJ to WT will rescue the mutant.  Prime 
Energy breaks down the energetics terms (e.g. vdW, electrostatics, lipophilic, etc.).  
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Figure 2.2: The proposed thermodynamic model.  
 
 
 
 
 
2.2 Results 
 The change in energy was determined by subtracting the folded state energy of the 
system from the active state, with and without chaperone. The results appeared to be promising 
at first. Potential energies that were highly negative seemed to be rescuable by the chaperone 
whereas positive energies were un-rescuable. These negative results (Tables 2.1 and 2.2 and 
Figures 2.2 and 2.3) are placed here to highlight the significance of the factors that can affect 
false positive results.  
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Table 2.1: There are six mutants shown here to display the nature of the calculations. The 
potential energy was calculated at neutral pH without DGJ to simulate the state in the ER prior 
proper folding. The potential energy was also calculated for acidic pH with DGJ to simulate the 
state prior to restoring function in the lysosome.  
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Figure 2.3: The graph above shows the change in potential energy (computational calculation) 
as a function of the change in activity (from the Amicus activity database). There seemed to be a 
correlation between the energy and the activity. Red mutants are unresponsive to chaperone, 
green mutants are rescuable by chaperone, and blue mutants are difficult to predict.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A37T 
L36S 
D33G 
G35R 
D33Y 
L36F 
A37V P40L 
L36W 
P40S 
P40R 
P40A N34K 
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Mutant ΔPE (A chain) ΔPE (B chain) Average 
D33G -97 -23 -60 
D33Y -72 -40 -56 
N34K 83 19 51 
G35R -115 -100 -108 
P40A 86 30 58 
P40R 119 65 92 
 
Table 2.2: Drastic changes in potential energies between the two chains of the homodimer create 
unreliable results. 
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Mutation Chaperoning Success Occurrences in Database 
I > T 100% 9/9 
M > I 100% 6/6 
P > T 100% 5/5 
N > S 88% 7/8 
M > T 83% 5/6 
M > V 83% 5/6 
A > T 82% 9/11 
T > I 80% 4/5 
L > F 70% 7/10 
E > K 29% 2/7 
H > X 22% 2/9 
R > P 20% 1/5 
L > P 20% 3/15 
M > R 20% 1/5 
P > R 20% 1/5 
N > K 17% 1/6 
D > H 14% 1/7 
D > V 12% 1/8 
W > C 10% 1/10 
C > X 8% 3/38 
A > P 7% 1/14 
A > D 0% 0/7 
L > R 0% 0/7 
W > R 0% 0/7 
W > L 0% 0/5 
 
Table 2.3: Chaperoning Success by Mutation – These mutations are taken from the initial 
Amicus database (Benjamin 2017). Certain mutations respond well to chaperone (e.g. isoleucine 
to threonine) while others do not (e.g. leucine to arginine). X denotes any amino acid.  
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Figure 2.4: The percent increase with DGJ is plotted as a function of the change in energy of the 
system from the thermodynamic model.  
 
 
2.3 Discussion 
Prior to any energetics calculations performed by the computational software, the database 
was binned and organized by commonly occurring mutations (Table 2.3). By doing so, we can 
predict which mutants are likely or unlikely to respond to chaperone. For example, every 
instance of an isoleucine mutated to a threonine can be successfully rescued by the small 
molecule chaperone. Thus, if there are new mutations discovered, and there is a mutation from 
ILE to THR, we have higher confidence that DGJ will help fold the mutant enzyme. On the other 
hand, there are mutations that often respond poorly to the iminosugar. For example, only 3/38 
mutations from cysteines to other amino acids are rescuable, so we expect mutations that disrupt 
0
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the residues implicated in disulfide bonding to be non-amenable to the chaperone. This binning 
is useful because as new activity data are published, the table can be updated to see which 
mutants are rescuable. The categorization by mutant strategy works if there is an extensive 
database of activity data published for the protein-ligand system of interest.  
The residue analysis task yielded results that appeared to be promising. However, there were 
a few issues with the outputs that made them unreliable. The task calculated energies that varied 
greatly between the two chains of the homodimer (Table 2.2). While there appeared to be a 
correlation between the energetics and the activity data, it is difficult to select which energetics 
data to use (A or B chain) for the correlation. As a result, the asymmetric ligands were 
eliminated from the structures (e.g. xylose, NAG, waters). However, the outputs from the residue 
analysis task yielded large energy fluctuations as well. 
Figure 2.4 shows the results of the Prime calculations on 98 mutants. The calculations use an 
updated force field model (OPLS3e) to calculate the energetics of the system. The energies are 
calculated from the proposed thermodynamic model. The free energy of binding DGJ to the WT 
is not relevant to consider here since it is a constant value. The resulting rescue free energy will 
simply be scaled by this factor, and because we are comparing the mutants to each other, the 
scaling does not affect the outcome of the calculation. Ten mutants shown in this graph portray 
successful and unsuccessful chaperoning. Energies greater than -21 kcal/mol are predicted to be 
non-rescuable by chaperone whereas energies less than -32 kcal/mol are predicted to respond 
well to the chaperone. 
However, Prime fails to capture the chaperoning prediction of most of this subset of 
mutations. Using classical mechanical force fields and modeling distal mutations from the active 
site may be two reasons why the task fails to calculate the correct energies. Classical force fields 
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approximate charge locations and cannot obtain proper atomic energetics. Creating distal 
mutations seems to have a minimal effect on the system because there is no simulation of 
folding. During the minimization steps, the protein can relax, and heavy atoms are unable to 
move more than 0.3 angstroms. While there are energetic penalties introducing certain mutations 
(e.g. an arginine replaces a leucine), newly created poor contacts may be offset by newly created 
proper contacts. For example, inserting an arginine into a tight pocket where the leucine was may 
introduce many steric clashes between the arginine and its neighboring residues. However, after 
the system can minimize and create a bigger pocket for the arginine to fit, there may be a salt 
bridge that formed with a neighboring aspartate to offset the steric penalty, resulting in a similar 
total energy. For this reason, it is important to observe the protein-ligand system instead of just 
the mutated residue. Approximations in energy calculations due to classical force fields lead to 
compounding errors, especially for a relatively large system (i.e. the ~100 kDa homodimer 
GLA). Therefore, the energy reported by Prime may not accurately represent the system. 
Additionally, distal mutations are poorly represented by this model. 
While the two approaches cannot perfectly predict chaperoning success, using them in 
conjunction may be beneficial. After running the Prime calculation, if the mutant energy falls 
within the cutoffs (i.e. between -32 and -21 kcal/mol), a better prediction could be made by 
looking at Table 2.3. For example, A43T falls within the interval where chaperoning success is 
ambiguous; however, the table predicts that 9/11 alanines that are mutated to threonines are 
rescuable. Therefore, we can make a prediction with greater certainty that this mutant will 
respond well to chaperone.  
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CHAPTER 3 
PERFORMING GLIDE DOCKING SIMULATIONS TO BETTER UNDERSTAND THE 
BINDING ENERGETICS OF DGJ AND GALACTOSE TO WT AND MUTANT GLA 
3.1 Introduction 
 There proved to be little correlation between the computational energetics and the activity 
data when calculating total energies of the WT and mutant GLA systems. The hypothesis here is 
that perhaps the free energy of binding the chaperone to mutants may be correlated to the activity 
data. The goal is to first determine the free energy of binding DGJ to WT to compare it to the 
experimental value. If this holds true, perhaps the free energy of binding DGJ to mutants will be 
smaller, and a correlation may exist. Additionally, a positive control to run a docking simulation 
on would be galactose which binds less tightly to the active site of GLA. Glide is the package 
used to perform protein-ligand docking simulations.  
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3.2 Results 
 
Figure 3.1: The above shows a 2-D ligand interaction diagram for DGJ bound to GLA from the 
crystal structure (PDB ID: 3S5Y) 
 
The measured free energy of binding, from the inhibitor equilibrium constant 39 nM, for 
DGJ bound to GLA is -10.2 kcal/mol.  
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Figure 3.2: The above 2D ligand interaction diagram shows the Glide docking simulation of 
DGJ bound to GLA.  
 
 The calculated docking score from Glide for DGJ bound to GLA is -10.16 kcal/mol.  
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Figure 3.3: The above 2D ligand interaction diagram shows the Glide docking simulation of 
DGJ bound to the mutant N215S.  
 
The calculated docking score from Glide for DGJ bound to N215S is -10.23 kcal/mol. 
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Figure 3.4: The above 2D ligand interaction diagram shows the Glide docking simulation of 
DGJ bound to the mutant R301Q.  
 
The calculated docking score from Glide for DGJ bound to R301Q is -10.17 kcal/mol. 
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Figure 3.5: The above 2D ligand interaction diagram shows the Glide docking simulation of 
DGJ bound to the mutant D170A.  
 
The calculated docking score from Glide for DGJ bound to D170A is -9.42 kcal/mol. 
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Figure 3.6: The above 2D ligand interaction diagram shows the Glide docking simulation of 
DGJ bound to the mutant P40L.  
 
The calculated docking score from Glide for DGJ bound to P40L is -10.25 kcal/mol. 
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Figure 3.7: The above 2D ligand interaction diagram shows alpha-D-galactose bound to GLA 
from the crystal structure (PDB ID: 3S5Z).  
 
The measured free energy of binding, from the equilibrium constant 16 mM, for alpha-D-
galactose bound to GLA is -2.6 kcal/mol, -7.6 kcal/mol less than DGJ.   
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Figure 3.8: The above 2D ligand interaction diagram shows the Glide docking simulation of 
alpha-galactose bound to GLA.  
 
 
The calculated docking score from Glide for alpha-D-galactose bound to GLA is -6.76 
kcal/mol.  
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3.3 Discussion 
Docking was the next step to determine if a mutant was rescuable. To make sure the model 
system was correctly created, DGJ was docked to WT GLA first since we know the binding free 
energy from experimental data (~ -10.2 kcal/mol). DGJ adds an additional -7.6 kcal/mol of 
binding free energy compared to its analog, galactose. The docking results show that DGJ and 
galactose bind the enzyme with similar affinities and therefore energies. While the docking score 
for DGJ bound to GLA appears to be relatively accurate, it is difficult to trust the model system 
due to the inaccuracies of binding galactose to WT (the expected result is ~ -3 kcal/mol). 
Nonetheless, the value should be corrected for the concentration of the α anomer in the racemic 
mix compared to the β anomer of galactose.  
The two-dimensional ligand interaction diagrams (Figure 13) indicate that the docking was 
relatively successful. The two main differences that are evident from these diagrams are the lack 
of a hydrogen bond with a water molecule in the active site and the positions of the active site 
residues. The changing of the locations of the residues in the active site can be attributed to some 
flexibility in the angles of the hydroxyl groups with its neighboring residues and the incorrect 
calculation of orbital positions and overlaps.  
Some of the other mutants also show positive results. N215S and R301Q both respond to 
chaperone and have similar binding energies as WT. D170A disrupts the active site architecture 
and the ligand is unable to bind as tightly which is attributable by the lower docking score. 
However, P40L does not respond to chaperone and has a higher docking score than WT which 
leads to the conclusion that this model is insufficient in predicting the correct energies of binding 
and the system. Additionally, because D170A showed a decrease in binding affinity, perhaps 
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distal mutations, mutations that occur far from the active site, are not represented by this fixed 
approach to modeling.  
Although the WT binding free energy to DGJ is a positive result, the positive control 
(galactose) binding free energy proves that an alternate approach is required to model the 
energetics of the system. However, it may be useful to carry out these calculations for novel 
mutations near the active site that may be rescuable by chaperone.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 28 
 
CHAPTER 4 
USING MOLECULAR DYNAMICS TO MEASURE STRUCTURAL EFFECTS ON 
MUTATIONS DISTAL FROM THE GLA ACTIVE SITE 
 
4.1 Introduction 
 Glide docking proved to yield results that were reliable when dealing with just the GLA 
active site. Distal mutations were unable to be modeled correctly due to the rigid nature of the 
simulations. The next approach was to use molecular dynamics which takes a model system, 
dissolves it in a solvent, and predicts the trajectories of the atoms as a function of time. These 
simulations would be useful for the many mutations that occur far from the active site. The goal 
is to observe a conformational change in the protein (i.e. folding) when the chaperone is added to 
the system. Desmond is the package used to run molecular dynamics simulations.  
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4.2 Results 
Molecular Dynamics for DGJ binding to WT GLA 
 
 
  
Figure 4.1: The root mean square deviation of the protein and ligand during the 1.2 ns 
simulation for DGJ binding to WT GLA.  
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Figure 4.2: The root mean square fluctuation of the protein during the 1.2 ns simulation for DGJ 
binding to WT GLA. The residue index indicates the position of the residue in the crystal 
structure (α-GAL is a homodimer and thus the graph includes both chains). Because the signal 
sequence is nonexistent in the coordinates, residue index 0 refers to L32 for α-GAL.  
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Figure 4.3: The RMSF of the individual atoms of the ligand are plotted, indicating the level of 
flexibility in the active site pocket.  
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Figure 4.4: The bar graph above shows the fractional interactions of the active site residues with 
the ligand, DGJ.   
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Figure 4.5: The graph above shows when the contacts are made with the active site residues 
during the simulation.  
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Figure 4.6: Ligand-protein interaction diagram for native GLA. 
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Molecular Dynamics Results for N215S 
N215S with bound active site: 
 
 
Figure 4.7: The above graph shows the RMSD of the protein, ligand, and side chains for N215S. 
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Figure 4.8: The above graph shows the RMSF of N215S by residue. Green indicates ligand 
contacts, and secondary structure is represented by the background vertical stripes (blue denotes 
beta sheet formation and red denotes alpha helix formation).   
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Figure 4.9: The RMSF of the individual atoms of the ligand are plotted, indicating the level of 
flexibility in the active site pocket. 
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Figure 4.10: Protein-ligand interaction diagram for the mutant, N215S. 
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Apo N215S: 
 
 
 
Figure 4.11: The above graph shows the RMSD of the protein and side chains of apo N215S.  
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Figure 4.12: The graph above shows the RMSF of apo N215S during the 1.2 ns simulation.  
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4.3 Discussion 
 The root mean square deviation (RMSD) is a tool used to measure the average change in 
displacement of a particular atom for a specific frame. The protein RMSD can be monitored to 
obtain structural information, such as conformational changes or if a system has achieved 
equilibrium. Fluctuations in the graph towards the end of the simulation indicate that the system 
has not equilibrated and must therefore be run for a longer interval. The ligand RMSD shows 
how stable a ligand is in the active site pocket of the protein. If the values differ greatly from the 
protein RMSD values, then the ligand most likely shifted away from the active site. We see 
similar results for the ligand and protein RMSD values, so we can conclude that the chaperone 
binds very tightly and does not destabilize the protein.  
 The root mean square fluctuation (RMSF) is used to measure local changes along a 
protein chain. Peaks would indicate portions of the protein where there is high fluctuation (e.g. 
this sometimes happens near the N and C termini). Secondary structures are typically more 
structured and are therefore less flexible. It seems the regions of flexibility occur near the C 
terminus of the protein and near residue numbers 140-160.  
 The ligand RMSF (Figure 4.9) measures the atomic fluctuation of the ligand. It may 
provide insight into which elements of the ligand are responsible for the different contacts in the 
active site. There is little flexibility of each of the atoms in the ligand indicating that the 
chaperone is bound tightly in the pocket.  
 The protein-ligand contacts bar graph (Figure 4.4) shows a summary of the types of 
contacts the ligand makes with the active site residues. Hydrogen bonds have the following 
properties: a bond length of at most 2.5 angstroms between the donor and acceptor atoms, a 
donor angle of at least 120 degrees between the donor-hydrogen-acceptor atoms, and an acceptor 
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angle of at least 90 degrees between the hydrogen-acceptor-bonded atoms. Hydrophobic contacts 
are divided into three categories: pi-cation, pi-pi, and non-specific interactions. Pi-cation 
interactions involve aromatic and charged groups within 4.5 angstroms. Pi-pi interactions 
involve the stacking of aromatic groups, and non-specific interactions involve hydrophobic 
sidechains that fall within 3.6 angstroms of a ligand’s aromatic or aliphatic carbons. Ionic 
interactions involve two oppositely charged atoms that are within 3.7 angstroms but do not form 
a hydrogen bond. Lastly, water bridges are hydrogen-bonded protein-ligand interactions that are 
mediated by a water molecule. The number of contacts each residue makes during the 250 
frames are also plotted. Darker shades of orange make more than one contact with the ligand.  
 The ligand-protein contacts show which active site residues participated in contacts 
during the simulation. D170, the active site nucleophile, contacts the ligand the entire simulation. 
Interesting to note here is the water bridge that appears to be vital near the active site. D266 
appears to have a water molecule mediate a hydrogen bond, thus increasing the stability of the 
ligand in the pocket.  
 The mutant, N215S, appears to be stabilized upon the addition of the small molecule 
chaperone. The side chains show less flexibility, similar to the WT enzyme values, indicating 
stability (2.25 RMSD vs. 2.0) While the ligand moves around more in the active site, part of this 
result may be attributable to a low simulation time (i.e. the system has not achieved equilibrium).  
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
5.1 Conclusions 
Lysosomal storage disorders are a group of metabolic diseases that manifest due to 
deficiencies of acid hydrolases needed to catabolize their substrates. These deposits lead to the 
swelling of cells which lead to tissue damage and eventual organ failure. FD is a lysosomal 
storage disorder that can serve as a model for other protein folding diseases. An activity database 
of FD mutants was used to test computational correlations in order to predict successful 
chaperoning effects.  
Residue Analysis and Prime Energy were used to determine total system energies to 
calculate the correct rescue energies based on the propose thermodynamic model. Unfortunately, 
there was a low correlation between the activity data and these computational results, indicating 
that perhaps a more intensive procedure (Glide docking) was required to simulate the energetics 
of the system.  
The initial docking of DGJ to the WT GLA yielded a positive result, with the 
computation agreeing with the measured binding free energy. However, distal mutations (such as 
P40L) and galactose (the endogenous substrate) generated unexpected docking scores. P40L, 
which does not respond to chaperone, showed an increase in binding free energy compared to the 
WT. Similarly, galactose displayed a binding free energy a few kcal/mol higher than the 
measured value. 
Molecular dynamics is a tool used to simulate the dynamic changes of a system and can 
plot trajectories as a function of time. This is useful because the whole system can move upon 
modeling a mutation distal from the active site. The WT enzyme bound to DGJ shows minimal 
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fluctuations of the ligand within the pocket of the active site and side chains, indicating DGJ 
stabilizes the protein. Similarly, N215S was stabilized by the addition of DGJ. While the 
deviations and fluctuations were relatively small (less than 0.5 angstroms), running the 
simulation for a long period of time may provide insight to the instability of the mutants. 
Additionally, MD can be useful for determining energies per frame. Running simulations on 
galactose and other positive controls would validate the model system.  
The greatest obstacle to overcome in the field of computational modeling is insufficient 
computing power. As a result, computations must be simplified and approximated, which is the 
case with the classically derived force field and solvent models. From the field of quantum 
mechanics, it is already known how to solve the orbital shape and energetics of a hydrogen atom 
and approximate, to great certainty, heavier atoms. Jaguar, a package in Schrödinger that uses 
quantum mechanics derived force fields, incorporates many of these quantum calculations; 
however, the computing power is not readily available. GPU clusters are expensive and quantum 
computing is still in the research and development phase. These limitations hinder the output of 
accurate results.  
 The proposed thermodynamic model may work if the energies are properly calculated. 
The approximations lead to compounding errors for large systems and the outputs are therefore 
inaccurate portrayals. Applying this model when computations become more accurate and 
reliable may lead to more accurate predictions of successful chaperoning. Additionally, 
molecular dynamics simulations could be useful if they are run for longer periods of time, 
allowing for the system to equilibrate. While the specific results are applicable to FD, these 
protocols could be applied to other lysosomal storage disorders and protein folding diseases, 
such as Gaucher, Pompe, Alzheimer’s, Parkinson’s, and Huntington’s diseases.  
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5.2 Future Directions 
Running Prime energetics calculations on the rest of the mutations would yield valuable 
information regarding mutant amenability to chaperone. The proposed thermodynamic model 
may still be applicable to determine the free energy of binding chaperone to a mutant structure. 
Further molecular dynamics simulations can be run to observe conformational changes upon 
modeling mutations, especially ones buried within the enzyme and not easily accessible to 
solvent.  
Perhaps the solution requires binning of mutations. Organizing the mutants by position in the 
enzyme, whether they participate in secondary structure formation, accessibility to solvent, or 
mutation type (i.e. charged, hydrophobic, size, etc.) would provide a better set of rules to predict 
successful chaperoning. Generating a flowchart that prioritizes certain categories (e.g. Step 1: Is 
the mutation part of the active site architecture?) may lead to a successful binning of mutants.  
Running energetics calculations on the molecular dynamics simulations would also prove to 
be useful to validate the model and observe differences between mutant structures and their 
bound counterparts. Additionally, simulated annealing could be performed to calculate an 
observed global minimum in energy. Other tools such as machine learning or QSAR, may also 
prove to be useful in determining which parameters are important to consider. Some of these 
tools are part of the KNIME package in the Schrödinger Suite. 
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CHAPTER 6 
 
MATERIALS AND METHODS 
 
All packages came from the 2019-2 release of the Schrödinger Suite. Maestro is the main 
interface for graphical uses.  
 
6.1 Residue Analysis System Refinement 
The coordinates were imported to Maestro and mutations were created by altering a WT 
residue to a FD reported mutation. Explicit hydrogens were added, and disulfide bonds were 
created (5 for GLA). Protonation states were calculated for the ligand, DGJ at a user-input pH 
(7.2 to simulate ER pH and 4.7 to simulate lysosomal pH). The hydrogen bonding network was 
optimized by sampling all states for hydrogen-bond clusters. This involved flipping dihedral 
angles for residues, such as asparagine, glutamine, and histidine, and a Monte Carlo algorithm 
was run to pick the angle and length that had the least penalties. After the optimization step, the 
structure was minimized. Hydrogens are minimized first, then heavy atoms are minimized to a 
RMSD of 0.3 angstroms. During this process, poor contacts, overlapping atoms, and incorrect 
dihedral angles are corrected (Sastry 2013).  
 
6.2 Prime Energy, Glide, and Desmond Structure Refinement 
The coordinates were imported to Maestro and mutations were created by altering a WT 
residue to a FD reported mutation. Explicit hydrogens were added, and disulfide bonds were 
created (5 for GLA). Protonation states were calculated for the ligand, DGJ at a user-input pH 
(mostly 7.2 to simulate ER pH). After the structure was preprocessed, all of the post-translational 
modifications (such as N-linked glycans), sugars (such as xylose), waters, and other artifacts of 
the crystal structure were deleted. Next, the hydrogen bonding network was optimized by 
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sampling all states for hydrogen-bond clusters. This involved flipping dihedral angles for 
residues, such as asparagine, glutamine, and histidine, and a Monte Carlo algorithm was run to 
pick the angle and length that had the least penalties. After the optimization step, the structure 
was minimized. Hydrogens are minimized first, then heavy atoms are minimized to a RMSD of 
0.3 angstroms. During this process, poor contacts, overlapping atoms, and incorrect dihedral 
angles are corrected (Sastry 2013). 
6.3 Residue Analysis Task 
The Residue Analysis task was run after the structure was processed. The parameters of 
interest were interaction energy, internal energy, and potential energy. The potential energy is the 
sum of the interaction and internal energy terms.  
6.4 Prime Energy Task 
After the structure was preprocessed, optimized, and minimized, it is ready for energy 
calculations. We used Prime energy to calculate the total energy of the different states (i.e. WT, 
mutant, bound WT, and bound mutant). The changes in free energy were measured as the 
difference between the final state and the initial state, based on the thermodynamic model 
proposed above. The two changes in free energies calculated from Prime energy were ΔGmutant 
and ΔGmutant+DGJ. ΔGbind was calculated using Glide docking, which will be explained in the next 
chapter.  
6.5 Ligand Preparation 
 The ligand was stripped from the crystal structure (PDB ID: 3S5Y for DGJ or PDB ID: 
3S5Z for alpha-D-galactose) and prepared using LigPrep in Maestro. Ionization states were 
created at pH 7.2 (to simulate ER pH) using Epik. The ligand was desalted, and tautomeric states 
were generated. The stereochemistry was conserved from the crystal structure.  
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6.6 Receptor Grid Generation 
 A receptor grid was generated to confine the binding of the ligand to a small box. The 
docked ligand served as the centroid for the simulation, and residues with hydroxyl groups near 
the active site could rotate during the docking simulation.  
6.7 Glide Docking Task 
 After the receptor grid had been generated, the docking simulation was performed. The 
van der Waals radii was scaled to 0.8 to decrease the potential for the nonpolar parts of the 
ligand. The ligand sampling was flexible, allowing for the sampling of nitrogen inversions and 
ring conformations. A docking minimization was performed prior to outputting a Glide docking 
score that correlates to the binding free energy.  
6.8 Molecular Dynamics Task 
Molecular dynamics (MD) simulations were performed using the Desmond package in 
Schrödinger, developed by D.E. Shaw Research. First, the prepared structure was used to create 
a model system to run for MD simulations. The solvent model used was TIP3P, the standard 
explicit water solvent recommended by Schrödinger. The boundary conditions were set as the 
size of the unit cell for the crystal structure (a = 137, b = 183, c = 48, angles = 90 degrees). 
Sodium ions were added to neutralize the overall negative charge of the homodimer and were 
placed at least 20 angstroms from the center of the ligand. The concentration of sodium chloride 
in the solvent system was 150 mM. The force field used to create proper contacts was OPLS3e, 
and the solvent model employed was VSGB 2.0.  
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After the system was prepared, a molecular dynamics simulation was run. The simulation 
time was 1.2 ns and the recording interval was 4.8 ps. The number of frames recorded was 250 
under atmospheric pressure at 300 K.  
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APPENDIX 
SETTINGS AND PYTHON SCRIPTS 
I. Protein Preparation Wizard Settings 
 
The following script will run through the default settings, but I will list the specifics here. In 
the “Import and Process” panel of the Protein Preparation Wizard, the following are selected: 
Assign bond orders, Use CCD database, Add hydrogens, Create zero-order bonds to metals, Create 
disulfide bonds, Delete waters beyond 5.00 angstroms from het groups, and Generate het states 
using Epik: pH 7.2 ± 2.0. All ligands were deleted in the “Review and Modify” panel. Waters that 
make direct contacts with the ligand (e.g. hydrogen bonds) remained. The number will change 
depending on the crystal structure. In the “Refine” panel, the following are selected: Sample water 
orientations, Use PROPKA pH 7.2. Click optimize and run a minimization using the OPLS3e force 
field and while converging heavy atoms to a RMSD of 0.3 angstroms.  
II. Prime Energy and Residue Analysis Settings 
There are no advanced settings for these tasks. You may simply search for them in the search 
bar and run them.  
III. Protein Preparation Wizard Job Automation Script 
 
# Schrodinger Script - protein preparation wizard and residue analysis task 
 
# import packages 
from schrodinger import structure 
from schrodinger.structutils import analyze, build 
from schrodinger.job import jobcontrol 
import pandas as pd 
 
# define function to call in Maestro 
def process_csv(): 
 
# read in csv file to pandas dataframe 
    df = pd.read_csv('mutant_data.csv', index_col=False) 
# iterate through each mutant in excel database 
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    for index, row in df.iterrows(): 
        mutant = row["Mutant"] 
        atom_num = row["Atom Number Chain A"] 
        atom_num2 = row["Atom Number Chain B"] 
        residue_id = row["Residue ID"] 
         
        PDB_FILE = "3S5Y.pdb" 
        RECMUT_BASENAME = "3S5Y_recep_mut" 
 
        # imports structure 
        pdb_st = structure.Structure.read(PDB_FILE) 
 
        # get atom number 
        at_in_resA = pdb_st.atom[atom_num] 
        at_in_resB = pdb_st.atom[atom_num2] 
        # mutate residue (parameters are structure name, atom_in_res, res_type) 
        build.mutate(pdb_st, at_in_resB, residue_id) 
        build.mutate(pdb_st, at_in_resA, residue_id) 
 
        # creates list of indices for ligand atoms in structure  
        ligand_ats = analyze.evaluate_asl(pdb_st, "ligand") 
        # deletes ligand (parameters are indices, renumbering atom list) 
        pdb_st.deleteAtoms(ligand_ats) 
 
        # write out mutated receptor structure 
        pdb_st.write("%s.mae" % RECMUT_BASENAME) 
 
        # run minimization job and wait for it to finish 
        ppw_cmd = ["prepwizard", 
                   "-propka_pH", 
                   "7.2", 
                   "%s.mae" % RECMUT_BASENAME, 
                   "%s_prepared.mae" % (mutant)] 
        job = jobcontrol.launch_job(ppw_cmd) 
        print("Launched preparation job (%s)" % job.JobId) 
        job.wait() 
        print("Preparation job %s" % job.ExitStatus) 
 
# run residue analysis 
# The '-HOST localhost' prevents the script from running outside Job Control 
ra_cmd = ["run", 
          "residue_analysis_backend.py", 
          "-HOST", 
          "localhost", 
          "-jobname", 
          "%s_analysis" % RECMUT_BASENAME, 
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          "%s_prepared.mae" % RECMUT_BASENAME] 
job = jobcontrol.launch_job(ra_cmd) 
print("Launched analysis job (%s)" % job.JobId) 
job.wait() 
print("Analysis job %s" % job.ExitStatus) 
 
IV. Docking Settings (Glide) 
a. Ligand Preparation (LigPrep) 
Strip the ligand from the crystal structure by using the Project Table. Select the structure, and 
pick “Split in place.” Use the ligand only structure for the LigPrep panel. The following are 
selected before running the preparation job: Force field: OPLS3e, Generate possible states at 
target pH 7.2 ± 2.0 using Epik, Desalt, Generate tautomers, Determine chiralities from 3D 
structures, Generate at most 32 per ligand, Output format: Maestro. 
b. Receptor Grid Generation 
The following are selected for each panel in “Receptor Grid Generation:” Pick to identify the 
ligand (Molecule), Scaling factor: 1.0, Partial charge cutoff: 0.25. The Center will be assigned 
after selecting the ligand. Select all rotatable groups to allow for rotation and run the job.  
c. Ligand Docking 
Import the receptor grid and the ligand to be docked (from LigPrep). In the “Ligands” panel, 
select the following: Do not dock or score ligands with more than 500 atoms, Do not dock or 
score ligands with more than 100 rotatable bonds, Scaling factor: 0.8, Partial charge cutoff: 0.15. 
In the “Settings” panel, select the following: XP, Write XP descriptor information, Flexible (for 
flexible docking) or Rigid (for rigid docking), Sample nitrogen inversions, Sample ring 
conformations, All predefined functional groups, Add Epik state penalties to docking score. Run 
the job and record the docking score from the XP descriptor file.  
V. Molecular Dynamics Settings (Desmond)  
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a. System Builder 
In the “Solvation” panel, select the following: Predefined: TIP3P, Box shape: orthorhombic, 
Distances (will vary per crystal structure so add in dimensions from the PDB), click Minimize 
Volume. In the “Ions” panel, select the following: Exclude ion and salt placement within 20 
angstroms of  “the ligand” (select this), Neutralize by adding n sodium cations (the program will 
calculate it for you by selecting “Recalculate”), Add salt, Salt concentration: 0.15M, ions are 
sodium and chloride.  
b. Molecular Dynamics 
The following are selected: Simulation time (ns): 1.2, Recording interval (ps): 4.8, energy: 
1.2, Approximate number of frames: 250, Ensemble class: NPT, Temperature (K): 300, Pressure 
(bar): 1.01325, Relax model system before simulation, Run.  
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